A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease
about
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adultsSecondary treatment of acute graft-versus-host disease: a critical reviewThe role of EMMPRIN in T cell biology and immunological diseasesIn vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-diseaseEndpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statementCurrent and future approaches for control of graft-versus-host disease.Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo.The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78.Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.How I treat refractory acute GVHD.Basigin is a druggable target for host-oriented antimalarial interventions.First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.Advances in the treatment of acute graft-versus-host disease.Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.Acute graft-versus-host disease: new treatment strategies.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.Basigin: a multifunctional membrane protein with an emerging role in infections by malaria parasites.Current clinical management of Fanconi anemia.Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies.CD147 blockade as a potential and novel treatment of graft rejection.Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells.Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgMLong-term follow-up of corticosteroid refractory acute GVHD treated with an Inolimomab-based algorithm: a single center experience.Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease.ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation.Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.α1-Antitrypsin Infusion for treatment of Steroid Resistant Acute Graft-versus-Host Disease.Regional intra-arterial steroid treatment in 120 patients with steroid-resistant or -dependent GvHD.
P2860
Q24200813-C64D117B-1638-476B-923E-CE08AC8C74D5Q26823275-680B5319-3C0D-45E7-B438-020231EDCB2FQ26998829-7EC90172-3A91-421B-9C11-2BCC8F585ABDQ27307168-EEE48094-B998-4286-97F6-72DFF0EE41BBQ33622648-02F0F8F2-39D1-4655-997D-FEF77CED934FQ33642625-D190DEE7-01C3-47F8-984A-898AE2C1269DQ34489151-AA158DC1-BEB2-4B7D-9243-74E2D4CF20E1Q34718149-61F8CDEC-1A1F-4361-B980-BEF790784150Q35760517-BFEA8C39-8855-4C61-B297-96010457ECF2Q35828633-A4D99FE2-B600-4C08-9D15-64FC46909C6FQ35894355-9F9F9649-9A3A-4C28-8E5D-EE8937CF44A3Q36113205-5F002E82-FCEF-474D-8E0C-899C8BADE471Q37191057-4B2EB6D8-E62B-418E-8E61-1667A3EB8CE4Q37468247-42BDF8E6-C47E-4783-A0A4-CD5A7AD417DCQ37610714-6B3DB945-4047-449F-9379-C5F724AB52BAQ37810286-7E6E5DB1-70DA-4270-B583-9B4DE574A37EQ37993738-48060855-D08C-4AD6-ADD5-4E2DBEC27632Q38033589-49DF6343-36ED-41C0-B749-609A17A1AD0EQ38059251-57F7AAAA-CB1B-48CE-B391-BB23C4DFFB2CQ38226527-E44EF280-6919-4B8A-B707-28B5721CFD4FQ38604527-88BE2E5D-69FD-4A81-ACF8-FCFA2CED2DCFQ41121054-79A715BD-685D-4E38-905F-5296C77305E8Q41273804-7ED64682-09AC-47F8-A94C-CD0C76A9A407Q42270601-52862134-61FC-4A99-98E3-D034B2313BACQ43273885-D151B5A8-24F5-4C12-A4FB-378285B1A8EBQ47114028-E5DD40DA-7661-4012-9E49-A7E2A545859DQ48362201-9BEE7F74-F493-4594-BA3C-740018F61A1CQ49679320-7A2A8B9B-883B-451A-BFDC-A3F201F921F5Q50044411-6DF2109E-AB46-43FB-8BB8-3A6814F8F3A4Q50561008-52ADAA47-0253-423E-BCA5-51E5E7A43B6C
P2860
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A phase 2/3 multicenter random ...... cute graft-versus-host disease
@ast
A phase 2/3 multicenter random ...... cute graft-versus-host disease
@en
A phase 2/3 multicenter random ...... cute graft-versus-host disease
@nl
type
label
A phase 2/3 multicenter random ...... cute graft-versus-host disease
@ast
A phase 2/3 multicenter random ...... cute graft-versus-host disease
@en
A phase 2/3 multicenter random ...... cute graft-versus-host disease
@nl
prefLabel
A phase 2/3 multicenter random ...... cute graft-versus-host disease
@ast
A phase 2/3 multicenter random ...... cute graft-versus-host disease
@en
A phase 2/3 multicenter random ...... cute graft-versus-host disease
@nl
P2093
P921
P1433
P1476
A phase 2/3 multicenter random ...... cute graft-versus-host disease
@en
P2093
Charles Linker
Daniel Couriel
Daniel J Weisdorf
Gisela Schwab
Helen E Heslop
John Dipersio
Lorin Roskos
Margaret L Macmillan
Mary Territo
Nancy Havrilla
P304
P356
10.1182/BLOOD-2006-08-013995
P407
P577
2007-03-15T00:00:00Z